Chronic Hepatitis News

The FDA has declined to approve Dynavax’s supplemental biologics license application for the expanded use of its four-dose hepatitis B vaccine regimen in adult patients on hemodialysis, according to a manufacturer’s press release.

Hepatitis C primary infection and reinfection incidences declined after the introduction of access to direct-acting antiviral hepatitis C treatments, researchers found.

Scaling up hepatitis C testing and treatment in prisons effectively reduced HCV incidence and was a cost-effective option compared with existing services, data from a study in Australian prisons showed.

As viral hepatitis continues to be a major health concern in the infectious disease field, recent research has highlighted the importance of testing and treatment.

BOSTON — A regimen of sofosbuvir/velpatasvir with ribavirin was effective among patients with refractory chronic hepatitis C virus with liver cirrhosis and chronic kidney disease, according to data presented at The Liver Meeting.

Tenofovir disoproxil improved long-term overall and recurrence-free survival rates compared with entecavir among patients with hepatitis B virus-related hepatocellular carcinoma who underwent liver resection.

BOSTON — Mortality rates were consistently lower in patients with severe alcohol-associated hepatitis treated with steroids during vs. before the COVID-19 pandemic, suggesting infection mitigation may have benefited this population.

BOSTON — Triple combination of vebicorvir, imdusiran and nucleos(t)ide reverse transcriptase inhibitor did not improve markers of active hepatitis B infection in virologically suppressed patients vs. treatment regimens without vebicorvir.

After assessing a national cohort of U.S. veterans with chronic hepatitis B, researchers found that only about half were on antiviral therapy, although they identified some potential factors associated with lack of timely treatment.

Alcohol use at initiation of direct-acting antiviral treatment was not associated with reduced odds for achieving sustained virologic response among veterans with chronic hepatitis C virus infection, according to data in JAMA Network Open.